These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12452751)

  • 21. Effect of soy milk on warfarin efficacy.
    Cambria-Kiely JA
    Ann Pharmacother; 2002 Dec; 36(12):1893-6. PubMed ID: 12452752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature.
    Parrish RH; Pazdur DE; O'donnell PJ
    Pharmacotherapy; 2006 Nov; 26(11):1650-3. PubMed ID: 17064211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids.
    Jalili M; Dehpour AR
    Arch Med Res; 2007 Nov; 38(8):901-4. PubMed ID: 17923275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database.
    Knudsen JF; Sokol GH
    Pharmacotherapy; 2008 Apr; 28(4):540-8. PubMed ID: 18363538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased anticoagulant activity of warfarin used in combination with doxifluridine.
    Nakajima M; Genda T; Suehira M; Satoh H; Miki A; Hori S; Sawada Y
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):969-72. PubMed ID: 20107800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin resistance due to sulfasalazine.
    Teefy AM; Martin JE; Kovacs MJ
    Ann Pharmacother; 2000 Nov; 34(11):1265-8. PubMed ID: 11098339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Warfarin Dosages and International Normalized Ratios Before and After Roux-en-Y Gastric Bypass Surgery.
    Steffen KJ; Wonderlich JA; Erickson AL; Strawsell H; Mitchell JE; Crosby RD
    Pharmacotherapy; 2015 Sep; 35(9):876-80. PubMed ID: 26406775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probable drug interaction between warfarin and hormonal contraceptives.
    Zingone MM; Guirguis AB; Airee A; Cobb D
    Ann Pharmacother; 2009 Dec; 43(12):2096-102. PubMed ID: 19934391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between warfarin and cannabis.
    Damkier P; Lassen D; Christensen MMH; Madsen KG; Hellfritzsch M; Pottegård A
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):28-31. PubMed ID: 30326170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring.
    Aomori T; Fujita Y; Obayashi K; Sato H; Kiyotani K; Nakamura K; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2014 Jun; 39(3):319-21. PubMed ID: 24612117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential interaction involving warfarin and ritonavir.
    Knoell KR; Young TM; Cousins ES
    Ann Pharmacother; 1998 Dec; 32(12):1299-302. PubMed ID: 9876810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction between warfarin and nafcillin: case report and review of the literature.
    Kim KY; Frey RJ; Epplen K; Foruhari F
    Pharmacotherapy; 2007 Oct; 27(10):1467-70. PubMed ID: 17896903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Individual differences in prothrombin time-international normalized ratio variation following coadministration of the anticancer agents S-1 and warfarin: 3 case reports.
    Yamamuro F; Miki A; Kondo G; Maeda T; Satoh H; Hori S; Sawada Y
    Int J Clin Pharmacol Ther; 2011 Nov; 49(11):700-4. PubMed ID: 22011696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
    Paulzen M; Finkelmeyer A; Grözinger M
    Pharmacopsychiatry; 2011 Nov; 44(7):317-23. PubMed ID: 21979923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
    van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
    Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal.
    Riesenman C
    Pharmacotherapy; 1995; 15(6 Pt 2):84S-99S. PubMed ID: 8587855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
    DeVane CL; Gill HS
    J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.